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POCUS ISSUE: TREATMENT OF BIFURCATION LESIONS
he FRONTIER Stent Registry
afety and Feasibility of a Novel Dedicated Stent
or the Treatment of Bifurcation Coronary Artery Lesions
hierry Lefèvre, MD,* John Ormiston, MD,† Giulio Guagliumi, MD,‡ Heinz-Peter Schultheiss, MD,§
aurent Quilliet, MD, Bernhard Reimers, MD,¶ Philippe Brunel, MD,# Williams Wijns, MD,**
. J. Buettner, MD,†† F. Hartmann, MD,‡‡ Susan Veldhof, RN,§§ Karin Miquel, PHD,§§
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assy, Tours, and Nantes, France; Auckland, New Zealand; Bergamo and Mirano, Italy;
erlin, Bad Krozingen, and Lubeck, Germany; Aalst and Diegem, Belgium; and Rotterdam, the Netherlands
OBJECTIVES The goal of this study was to evaluate the safety and performance of the Multi-Link Frontier
coronary bifurcation stent system (Guidant Corp., Santa Clara, California), a novel dedicated
device designed for permanent side branch (SB) access, stent delivery by simultaneous kissing
balloon inflation, and optimal main branch (MB) and SB ostium scaffolding.
BACKGROUND The treatment of coronary bifurcation lesions remains challenging, and various approaches
using stents have been proposed.
METHODS The primary end point was the 180-day incidence of major adverse cardiac events (MACE)
per intent-to-treat analysis. Secondary end points included device success, 30-day MACE,
angiographic restenosis, and target lesion revascularization (TLR) rates at 180 days.
RESULTS After a learning phase of two cases per center, 105 patients were prospectively included in 11
centers. The left anterior descending coronary artery/diagonal bifurcation was the target in
80% of cases. The Frontier stent was successfully implanted in 96 patients (91%), and
procedural success was obtained in 93%. Two patients suffered in-hospital myocardial
infarction (MI) secondary to SB occlusion, and one patient underwent elective coronary artery
bypass grafting. At 30 days and 6 months, the MACE rates were 2.9% and 17.1% (no death,
no subacute stent thrombosis, Q-wave MI 1.0% and 1.9%, non–Q-wave MI 1.0% and 1.9%,
TLR 1.0% and 13.3%). The MB in-stent restenosis was 25.3%, in-segment 29.9%. The SB
restenosis was 29.1%. The overall restenosis rate for any branch was 44.8%.
CONCLUSIONS The results of this Frontier registry demonstrate the safety and performance of this dedicated
stent system for the treatment of bifurcation lesions. The device can be successfully implanted
in more than 90% of all cases, with a high procedural success rate and low 30-day and
6-month MACE rates. (J Am Coll Cardiol 2005;46:592–8) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.033College of Cardiology Foundation
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sercutaneous treatment of coronary bifurcation lesions re-
ains challenging (1–19), and a variety of approaches using
issing, skirt, trousers, T stenting, and others have been
ublished (7,12,14–18). However, coronary stenting in
ifurcation lesions is still associated with a lower procedural
uccess and higher rate of restenosis compared with nonbi-
urcation lesions.
The Multi-Link (ML) Frontier coronary bifurcation
tent system (Guidant Corp., Santa Clara, California) is a
ovel dedicated device specifically designed for the treat-
From the *Institut Jacques Cartier, Massy, France; †Green Lane/Mercy Hospital,
uckland, New Zealand; ‡Ospedali Riuniti, Bergamo, Italy; §Hospital Benjamin
ranklin, Berlin, Germany; Hopital Trousseau, Tours, France; ¶Ospedale Civile,
irano, Italy; #Clinique St Henri, Nantes, France; **OLVG Aalst, Aalst, Belgium;
†Herz-Zentrum, Bad Krozingen, Germany; ‡‡Universitatsklinikum Lubeck, Lu-
eck, Germany; §§Guidant Europe, Diegem, Belgium; and  Erasmus Medical
entre, Rotterdam, the Netherlands. This study was supported by Guidant Corpo-
ation, Santa Clara, California. Susan Veldhof, Dr. Miquel, and Xiaolu Su are
mployees of Guidant Corporation. Dr. Guagliumi has a consultant agreement with
uidant.l
Manuscript received November 2, 2004; revised manuscript received March 8,
005, accepted March 22, 2005.ent of bifurcation lesions. The Frontier registry was set up
o investigate the safety and performance of this device for
he treatment of de novo or restenotic bifurcation lesions.
ETHODS
tudy population. Main inclusion criteria were stable,
nstable angina (Braunwald classification 1 to 2 A, B), or
ilent ischemia in patients with de novo or restenotic (no
n-stent restenosis) bifurcation lesion in a main branch
MB) vessel of a reference diameter 2.5 mm and 4.0
m (visually assessed) that could be covered by a total stent
ength of31 mm. Side branch (SB) diameter needed to be
2.0 mm. Patients with two-vessel disease were included if
he nonbifurcated lesion located in a different vessel was
uccessfully treated before the bifurcation procedure. Major
xclusion criteria were the presence of thrombus in the
arget lesion, a bifurcation angle 75° per visual estimation,
evere tortuosities or calcifications proximal to the target
esion, and left main lesions.
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August 16, 2005:592–8 The Frontier Stent Registrytudy device. The ML Frontier coronary stent system
onsists of an 18-mm balloon-expandable 316L stainless
teel stent premounted on a dedicated delivery system with
wo balloons and two guidewire lumens. The MB balloon
iameter is 2.5, 3, 3.5, or 4.0 mm, and the SB balloon 2.0
m for the 2.5- and 3-mm device and 2.5 for the 3.5- and
-mm device. The ML Frontier is compatible with 7-F
uides (inner diameter 0.78 inch). The stent is made of a
eries of 15 rings. The eight distal rings are made of six
rests, and the ninth ring of eight crests in order to
ccommodate the SB portal; the proximal six rings are made
f seven crests to accommodate the larger proximal MB
iameter. The delivery system is based upon a dual guide-
ire design: an over-the-wire inner lumen for the SB
alloon and a rapid exchange lumen for the MB balloon.
he design incorporates a common inflation lumen for
imultaneous inflation of the two balloons. In order to assist
ith tracking and avoid guidewire crossing, the MB balloon
ip includes a pocket on the distal sleeve for joining the MB
nd SB balloon tips with a mandrel.
tenting procedure. Eligible patients had predilation of
he target lesion after wiring both branches of the bifurca-
ion lesion. An ML Frontier stent of an appropriate size was
elected according to the distal reference of the MB. The
evice was back-loaded onto the MB wire and pushed up to
he lesion (Fig. 1A). After removing the joining mandrel
nd unjoining the balloon tips, a 300-cm wire was inserted
nto the SB balloon lumen and pushed into the MB. Then
he device was pulled back proximal to the bifurcation. The
ong wire was inserted into the SB (Fig. 1B), and the
reviously used SB wire for predilatation was removed.
hen the stent was advanced into position (Fig. 1C) by
imply pushing the device. The stent becomes in phase with
he bifurcation by a self rotation and is stopped at the level
f the carena. A resistance is felt, and correct positioning is
hecked by angiography. Then the stent is deployed by
imultaneous kissing inflation (Fig. 1D), and the delivery
ystem is removed (Fig. 1E). The SB may or may not be
osttreated by balloon or kissing balloon dilation, or stent
mplantation. Patients received aspirin (250 mg) and a
oading dose of clopidogrel (300 mg) before angioplasty. A
onventional bolus of 10,000 IU of unfractionated heparin
as given at the start of the procedure. The activated
Abbreviations and Acronyms
MACE  major adverse cardiac events
MB  main branch
MI  myocardial infarction
ML  Multi-Link
PCI  percutaneous coronary intervention
QCA  quantitative coronary angiography
SB  side branch
TLR  target lesion revascularization
TVR  target vessel revascularizationlotting time was monitored and kept at a therapeutic level
i
d250 s for the entire procedure. The use of glycoprotein
Ib/IIIa agents was left to the discretion of the investigators.
fter the procedure, all patients received aspirin (75
g/day for six months) and clopidogrel (75 mg/day for one
onth).
nd points and definitions. The aim of the Frontier
egistry was to investigate the safety and feasibility of the
L Frontier stent implantation. The primary end point was
ajor adverse cardiac events (MACE) at 180 days, defined
s death, Q-wave or non–Q-wave myocardial infarction
MI), and target lesion revascularization (TLR). Non–Q-
ave MI was defined as creatinine kinase 3 times the
igure 1. (A to E) Deployment sequence of the Frontier stent. (A) The
ystem is advanced into the main branch over a conventional rapid-
xchange wire. (B) The joining mandrel is retracted to release the
ver-the-wire side branch tip. A long guidewire is inserted into the side
ranch. (C) The system is advanced up to the carina. (D) With a single
nflation device, the stent is deployed by kissing balloon inflation. (E) After
eflation the delivery system is retracted.
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The Frontier Stent Registry August 16, 2005:592–8pper limit of normal with elevated MB fraction. Q-wave
I was defined as new pathological Q waves in two or more
eads in addition to elevated enzymes as above. Target lesion
evascularization was defined as MB and/or SB target site
evascularization by percutaneous coronary intervention (PCI)
r coronary artery bypass grafting. Target vessel revasculariza-
ion (TVR) was defined as any vessel revascularization.
Secondary end points were device success; procedural
uccess (defined as 50% residual diameter stenosis in both
ranches by quantitative coronary angiography [QCA] us-
ng the assigned device and without MACE at discharge);
ACE at 30 days; binary restenosis; and target vessel
ailure at 6 months (composite of death, Q-wave or non–
-wave MI, and TVR).
ngiographic analysis. Quantitative coronary angiography
as performed at baseline, after procedure, and at 180-day
ollow-up. Binary restenosis was defined as 50% diameter
tenosis in the MB or in the SB using an interpolated
ethod with validated edge detection algorithm (CAAS II
nalysis System, Pie Medical BV, Maastricht, the Nether-
ands). In-segment analysis was defined as SB to SB for the
igure 2. Bifurcation lesion classification from the Duke University An
rebranch stenosis not involving the ostium of the side branch. Type B: Po
able 1. Baseline Clinical Characteristics
n  105
ge, yrs (mean  SD) 62  11
ale gender, n (%) 77
urrent smoker, n (%) 28
iabetes requiring medication, n (%) 17
reated hypertension, n (%) 46
reated hypercholesterolemia, n (%) 65
revious MI, n (%) 36
revious CABG, n (%) 1
revious PTCA, n (%) 5
nstable angina (Braunwald class 1 to 2 A, B), n (%) 30
ABG  coronary artery bypass graft; MI  myocardial infarction; PTCA 
ercutaneous transluminal coronary angioplasty.ype C: Stenosis encompassing the side branch but not involving the ostium. T
ype E: Stenosis involving the ostium of the side branch. Type F: Stenosis diB proximal and distal to the bifurcation lesion and
ifurcation to SB for SB analysis.
ample size and statistical analysis. After a roll-in phase
f two patients per center, 100 patients were planned to be
ncluded in the registry. Although roll-in patients complied
ully with all the enrollment criteria, they were reported in
separate analysis.
The Frontier registry was powered to compare the pri-
ary end point of MACE at 180 days with previously
ublished studies (6,7,19–21) that used a strategy of MB
tenting with SB provisional T stenting. They reported a
ean MACE rate at six months of 39% (upper 95%
onfidence limit 51%). The statistical test used for this
nalysis was the exact Clopper-Pearson method (22). As-
uming the Frontier device had a 180-day MACE rate of
4%, 89 patients were required to be included in the study
o ensure a 95% statistical power. The primary end point
as reported on an intent-to-treat basis. The secondary end
oints are presented by a per-protocol analysis except for
evice and procedural success. For time-to-event variables
such as time to MI, TLR, MACE), survival curves were
onstructed using Kaplan-Meier estimates.
tudy organization. The Data and Safety Monitoring
oard and the Clinical Events Committee were separately
esignated groups of qualified individuals not involved in
he study, which monitored safety and adjudicated clinical
nd points respectively. The QCA analysis was performed
y an independent core laboratory (Cardialysis, Rotterdam,
he Netherlands). The trial sponsor was Guidant Corp.
ESULTS
etween May and October 2002, 25 patients were included
n the roll-in phase in 13 sites, and 105 patients were
nrolled in the study at 11 sites. Patient demographics in the
aphic Core Lab, Duke University, Durham, North Carolina. Type A:
ch stenosis of the parent vessel not involving the origin of the side branch.giogr
stbranype D: Stenosis involving the parent vessel and ostium of the side branch.
rectly involving the parent vessel and ostium of the side branch.
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August 16, 2005:592–8 The Frontier Stent Registrytudy group are summarized in Table 1 and bifurcation
esion types are described in Figure 2.
rocedural data. Procedural characteristics of the study
atients are summarized in Table 2. Device success was
1%, and procedural success 93%. The device could not be
elivered in eight cases because of vessel calcification and in
ne case because of wire wrap. In one patient, there was a
nal in-stent diameter stenosis 50%. The SB was stented
n 43% of cases.
ead-in cases. The clinical, angiographic, and procedural
haracteristics of the 25 lead-in cases were comparable to
he registry. Device success was obtained in 100% of cases
nd procedural success in 96%.
CA analysis. The results of QCA are reported in Table 3.
aseline reference vessel diameter of the MB and SB were
elatively small (2.77  0.51 mm and 2.10  0.67 mm,
espectively). Main branch lesion length was 12  6 mm. At
80 days’ follow-up, the MB late lumen loss was 0.84  0.55
m, in-stent binary restenosis 25.3%, and in-segment 29.9%.
he in-segment SB binary restenosis rate (Table 4) was 29.1%.
linical end point analysis. The in-hospital and 30-day
ierarchical MACE rates were both 2.9% (Table 5). At 180
ays, the MACE rate (the primary end point) was 17.1%,
nd the MB TLR rate was 15.2% (9.5% ischemia driven).
verall, ischemia-driven TLR (MB and/or SB) was 11.4%.
igure 3 shows the Kaplan-Meier survival curves for free-
om from MI, freedom from TLR, and freedom from
ACE, which were 96.2%, 83.6%, and 82.7% at 190 days,
espectively.
able 2. Lesion and Procedural Characteristics
Main
Branch
Side
Branch
eft anterior descending (%) 80 —
eft circumflex (%) 13 —
ight coronary artery (%) 7 —
CC/AHA class A (%) 2 27
CC/AHA class B1 (%) 21 61
CC/AHA class B2 (%) 77 13
oderate/severe calcification (%) 29 12
IMI flow grade 3 preprocedure (%) 91 93
ifurcation angle 75° by QCA (%) 71 —
esion length (mm) 12  6 4  3
redilation (%) 100 —
dditional stent at TL* (%) 40 —
ide branch treatment*
Balloon (%) — 38
Stent implantation across ML Frontier (%) — 43
None (%) — 20
inal kissing balloon technique* (%) 80 —
evice success by QCA† (%) 92 —
rocedural success by QCA‡ (%) 93 —
Per-protocol population (patients implanted with a Multi-Link [ML] Frontier
tent); †attainment of final residual stenosis 50% in the main branch using the ML
rontier stent; intent-to-treat population; ‡attainment of final residual stenosis50%
n both the main branch and side branch without any in-hospital major adverse
ardiac events; intent-to-treat population.
ACC/AHA  American College of Cardiology/American Heart Association;
CA  quantitative coronary angioplasty; TIMI  Thrombolysis In Myocardial
nfarction; TL  target lesion.
VISCUSSION
he main findings of the ML Frontier registry are the
ollowing: 1) despite the fact that this device is the first
eneration of a dedicated stent for treating bifurcation
esions, device success is relatively high (91%); 2) acute
atency of the SB is high (98% Thrombolysis In Myocardial
nfarction flow grade 3 after procedure); 3) safety is excel-
ent with a 2.9% MACE rate at one month, no cases of
ubacute or late thrombosis, and no death at 180 days; 4)
ate loss (0.84  0.55 mm) is comparable to late loss
bserved in nonbifurcation lesions treated with bare metal
tents and is associated with an acceptable ischemia-driven
LR of 11.4%.
able 3. Quantitative Coronary Angiography Analysis by
ore Laboratory (Per Protocol Population)
Variables
Main
Branch
(n  96)
Side
Branch
(n  96)
Any
Branch
(n  96)
aseline†
Reference diameter (mm) 2.77  0.51 2.10  0.67 —
MLD (mm) 1.07  0.35 1.23  0.45 —
Diameter stenosis (%) 61  12 39  18 —
ostprocedure
MLD (mm) 2.43  0.41* 1.47  0.40† —
Diameter stenosis (%) 15  10* 25  13† —
ix-month follow-up
MLD (mm) 1.59  0.56* 1.13  0.47† —
Diameter stenosis (%) 39  19* 39  21† —
In-stent binary
restenosis (%)
25.3 —‡ —
In-segment binary
restenosis (%)
29.9 29.1 44.8
Late lumen loss (mm) 0.84  0.55* 0.34  0.45† —
In-stent; †in-segment; ‡because only a minority of side branches were stented, no
ata is provided for the overall population. Values are mean  SD except restenosis
ates (%).
MLD  minimal lumen diameter.
able 4. Side Branch Quantitative Coronary Angiography
nalysis by Core Laboratory (Per-Protocol Population,
n-Segment Analysis)
Stented
Side
Branch
(n  41)
Ballooned
Side
Branch
(n  36)
Nontreated
Side
Branch
(n  19)
aseline
Reference diameter (mm) 2.32  0.79 2.01  0.53 1.81  0.54
MLD (mm) 1.17  0.46 1.27  0.44 1.30  0.43
Diameter stenosis (%) 47  19 37  14 27  15
Mean lesion length (mm) 4.5  3.3 3.8  2.3 3.4  1.9
ostprocedure
MLD (mm) 1.60  0.42 1.42  0.37 1.30  0.36
Diameter stenosis (%) 24  13 27  11 24  15
ix-month follow-up
MLD (mm) 1.04  0.56 1.22  0.35 1.19  0.40
Diameter stenosis (%) 44  26 34  14 38  15
Binary restenosis (%)* 35.9 19.4 31.3
p values: 35.9% vs. 19.4%: 0.1837; 19.4% vs. 31.3%: 0.4716; 35.9% vs. 31.3%: 1.00.
alues are mean  SD except restenosis rates (%).
MLD  minimal lumen diameter.
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The Frontier Stent Registry August 16, 2005:592–8he era of dedicated stents. Bifurcation lesions have been
reated for many years with a large variety of stenting
pproaches ranging from the simplest to the most complex.
ecause stents were not designed for treating bifurcation
esions and also because the main technical problem is the
isk of SB compromise during the procedure, a new para-
igm of dedicated stents appeared in the 1990s. Bifurcated
tents were, however, associated with a relatively low rate of
evice success (23) due to their rigidity and poor profile. As
consequence, the idea of treating the MB and protecting
he SB ostium of the bifurcation with a single dedicated
tent and delivery system emerged. This is the first con-
rolled study with angiographic follow-up on the use of a
edicated stent. Other devices developed by various com-
anies are currently being investigated.
evice success. Implantation of the ML Frontier with
ccess to the SB when required was obtained in 100% of
ases in the roll-in phase and 91% in the registry. The study
esults were obtained in quite complex lesions (77% type B2,
9% moderate-to-heavy calcification, and 29% had an
Table 5. Major Adverse Cardiac Events (MAC
Population)
In-Hospital
(n  105)
n (%)
Death 0 (0.0)
Q-Wave MI 1 (1.0)
Non–Q-wave MI 1 (1.0)
TLR by CABG or PCI 1 (1.0)
MACE 3 (2.9)
TVF 3 (2.9)
TVR excluding TLR 0 (0.0)
MACE is defined as death, non–Q-wave and Q-wave MI,
CABG of the treated lesion in the main branch and/or the si
and TVR. TVR is defined as revascularization including PC
any other lesion in the target vessel.
CABG  coronary artery bypass graft; MACE  maj
percutaneous coronary intervention; TLR  target lesion re
revascularization.igure 3. Kaplan-Meier curves: survival to 180 days, survival free of major adve
evascularization (TLR) (intent-to-treat population).ngulation 75°). It is interesting to note that, despite
imilar clinical and angiographic characteristics, the rate of
evice success in the roll-in phase was 100%, suggesting that
he learning phase is relatively short with this device, but
lso that easier cases were probably selected.
The SB was stented in 43% of cases, and failure of SB
tenting was not observed, suggesting an easy SB access
hrough the portal. In addition, the procedural success was
3%, at least in the same range as that of prior reported
bservational noncontrolled studies using bare-metal stents
7,20,21).
ngiographic outcome. The MB in-stent late loss of 0.84
0.55 mm is comparable to late loss observed in nonbi-
urcation lesions and associated with an acceptable binary
estenosis rate of 25.3%. The restenosis rate for both
ranches (44.8%) compares also favorably with the data of
amashita et al. (7) who reported binary restenosis rates of
2% and 48% in their study comparing different techniques
o treat bifurcation lesions, although the MB reference
essel size was smaller in the Frontier study (2.77  0.51
ierarchical Analysis (Intent-to-Treat
30  5 Days
(n  105)
n (%)
180  10 Days
(n  105)
n (%)
0 (0.0) 0 (0.0)
1 (1.0) 2 (1.9)
1 (1.0) 2 (1.9)
1 (1.0) 14 (13.3)
3 (2.9) 18 (17.1)
3 (2.9) 24 (22.9)
0 (0.0) 6 (5.7)
LR. TLR is defined as revascularization including PCI or
ch. TVF is defined as death, non–Q-wave and Q-wave MI,
ABG of the target lesion in the main and/or side branch or
erse cardiac events; MI  myocardial infarction; PCI 
rization; TVF  target vessel failure; TVR  target vesselE) H
and T
de bran
I or C
or advrse cardiac events (MACE), myocardial infarction (MI), and target lesion
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August 16, 2005:592–8 The Frontier Stent Registrym compared to 3.09  0.57 mm in the study by
amashita et al. [7]).
The lower in-segment restenosis rate (not significant)
bserved when SB was posttreated by balloon angioplasty
19.4%) compared to 35.9% when stented and 31.3% in
ases of no posttreatment shows similar trends toward better
utcome when using one stent compared to two stents as
bserved in previous studies (7,20,21,24–27).
linical outcome. The ML Frontier stent provided favor-
ble acute and long-term clinical results, as measured by
ACE at hospital discharge and at 30 and 180 days when
ompared to the literature (Table 6) (7,20,21,28). The
0-day MACE rate of 2.9% demonstrated no additional
isk of subacute MB or SB occlusions when using this
evice. The primary end point result, MACE at 180 days,
as 17.1% (95% upper confidence limit 25.7%), which was
ell below the 34% (95% upper confidence limit 51%)
alculated as an objective performance criterion when de-
igning the study (6,7,19–21). Ischemia-driven TLR was
1.4%, which compares favorably with previous uncon-
rolled published studies using a provisional T stenting
pproach (5,6,19–21,25).
tudy limitations. Limitations of the ML Frontier stents
re that they are larger in profile and less flexible than
onventional stents and, consequently, more difficult to
eliver in tortuous or calcified arteries, and require a guiding
atheter 7-F. A further limitation is that there are
urrently no dedicated devices that elute an antirestenotic
rug. In a recent study (28) in which patients were random-
zed to receive either one or two sirolimus-eluting stents,
estenosis rates were lower than historical bare metal stent
ontrols (Table 6). It is expected that in the future,
edicated bifurcation stents such as the ML Frontier will be
vailable coated with an antirestenotic medication and a
ower profile, which should broaden their applicability.
onclusions. The Frontier registry evaluated the first clin-
cal use of a novel dedicated stent system for the treatment
f coronary bifurcation lesions. The safety and efficacy of
his specifically designed stent allowing continuous SB
ccess were demonstrated with low in-hospital and 180-day
able 6. Comparison With Other Bifurcation Studies With Bare
Study n
In-Hospital M
%
efèvre et al. (20) Period 1 182 5.1
Period 2 191 4.2
amashita et al. (7) 2 stents 53 13
1 stent 39 0
l Suwaid et al. (21) 2 stents 54 5.6
1 stent 77 2.7
olombo et al. (28) 2 stents‡ 63 9.5§
1 stent‡ 22 9.1§
rontier 105 2.9
1 year; †target vessel revascularization; ‡sirolimus-eluting stent; §target vessel failur
MACE  major adverse cardiac events; RR  restenosis rate 50% binary resteACE.eprint request and correspondence: Dr. Thierry Lefèvre, Insti-
ut Hospitalier Jacques Cartier, Rue du Noyer Lambert, 91300
assy, France. E-mail: t.lefevre@icps.com.fr.
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